
Aravive ARAV
Quarterly report 2023-Q3
added 11-09-2023
Aravive Depreciation & Amortization 2011-2026 | ARAV
Annual Depreciation & Amortization Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 886 K | 974 K | 1.83 M | 498 K | 1.06 M | 311 K | 215 K | 194 K | 107 K | 17 K | 21 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.83 M | 17 K | 556 K |
Quarterly Depreciation & Amortization Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 215 K | - | 664 K | 443 K | 222 K | - | 746 K | 493 K | 240 K | - | 1.6 M | 1.15 M | 125 K | - | 373 K | 248 K | 126 K | - | 975 K | 236 K | 119 K | - | 190 K | 104 K | 54 K | - | 161 K | 106 K | 53 K | - | 174 K | 113 K | 54 K | - | 59 K | 18 K | 5 K | - | 12 K | 11 K | 5 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.6 M | 5 K | 294 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aptorum Group Limited
APM
|
1.13 M | $ 1.06 | -0.93 % | $ 5.78 M | ||
|
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.82 | -4.85 % | $ 464 M | ||
|
Adagene
ADAG
|
723 K | $ 1.65 | - | $ 92.9 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
22.2 M | $ 64.9 | -0.15 % | $ 8.68 B | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Biogen
BIIB
|
673 M | $ 187.4 | 0.75 % | $ 27.3 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
BioXcel Therapeutics
BTAI
|
309 K | $ 1.98 | -1.0 % | $ 5.02 M | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | ||
|
CASI Pharmaceuticals
CASI
|
468 K | $ 1.04 | -2.34 % | $ 142 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Catalyst Biosciences
CBIO
|
1.07 M | $ 10.74 | -2.1 % | $ 707 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Arena Pharmaceuticals
ARNA
|
3.87 M | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
1.43 M | - | 3.77 % | $ 22.4 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
3.18 M | $ 27.0 | -1.28 % | $ 1.74 M | ||
|
BioVie
BIVI
|
229 K | $ 1.27 | -2.31 % | $ 1.88 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
9.45 M | - | -15.15 % | $ 60.3 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
28.2 M | $ 27.75 | 0.02 % | $ 1.34 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 4.14 | -3.72 % | $ 9.01 B | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
24.9 M | $ 11.13 | -2.02 % | $ 720 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Axon Enterprise
AXON
|
48.4 M | $ 633.45 | 3.34 % | $ 48 B | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.64 | -0.75 % | $ 16.6 M | ||
|
BeiGene, Ltd.
BGNE
|
172 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K |